MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.380
+0.080
+6.15%
Opening 15:21 04/08 EDT
OPEN
1.350
PREV CLOSE
1.300
HIGH
1.387
LOW
1.330
VOLUME
12.60K
TURNOVER
--
52 WEEK HIGH
3.330
52 WEEK LOW
1.040
MARKET CAP
12.97M
P/E (TTM)
-0.6929
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLRB stock price target is 6.35 with a high estimate of 10.00 and a low estimate of 3.000.

EPS

CLRB News

More
  • Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update
  • GlobeNewswire · 03/09 13:00
  • Cellectar Biosciences Q4 EPS $(0.33) Down From $0.06 YoY
  • Benzinga · 03/09 12:03
  • VIAC, WIX among premarket losers
  • Seeking Alpha - Article · 02/20 14:17
  • GRPN, SLS, ENPH and SSTI among midday movers
  • Seeking Alpha - Article · 02/19 17:42

Industry

Pharmaceuticals
+3.51%
Pharmaceuticals & Medical Research
+3.40%

Hot Stocks

Symbol
Price
%Change

About CLRB

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
More

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.